Errant Gene Therapeutics (EGT) Wins Major Victory in New York Appeals Court

On April 30, 2020, the New York Supreme Court, First Department, Appellate Division unanimously affirmed rulings in our client EGT’s favor to proceed with fraud, unfair competition, and breach of contract claims in a trial against Bluebird Bio and Sloan Kettering Institute for Cancer Research.

The Appellate Court ruling stated that lower Supreme Court Justice Barry R. Ostrager was correct in deciding in our favor to deny Sloan Kettering and Bluebird Bio’s motions for summary judgment. “Contrary to defendant’s contentions, this court has already determined that [t]he measure of plaintiff’s damages as alleged, is not speculative as a matter of law”.